Combined methotrexate and hydroxyurea therapy for psoriasis

1973 ◽  
Vol 107 (3) ◽  
pp. 369-370 ◽  
Author(s):  
G. C. Sauer
Keyword(s):  
Hydroxyurea Therapy

Cutaneous ulcers following hydroxyurea therapy

Phlebologie ◽  
2004 ◽  
Vol 33 (06) ◽  
pp. 202-205 ◽  
Author(s):  
K. Hartmann ◽  
S. Nagel ◽  
T. Erichsen ◽  
E. Rabe ◽  
K. H. Grips ◽  
...  
Keyword(s):  
Side Effects ◽  
Side Effect ◽  
Antineoplastic Agent ◽  
Limited Time ◽  
Myeloproliferative Diseases ◽  
Dermatological Side Effects ◽  
Chronic Myeloproliferative Diseases ◽  
Hydroxyurea Therapy

SummaryHydroxyurea (HU) is usually a well tolerated antineoplastic agent and is commonly used in the treatment of chronic myeloproliferative diseases. Dermatological side effects are frequently seen in patients receiving longterm HU therapy. Cutaneous ulcers have been reported occasionally.We report on four patients with cutaneous ulcers whilst on long-term hydroxyurea therapy for myeloproliferative diseases. In all patients we were able to reduce the dose, or stop HU altogether and their ulcers markedly improved. Our observations suggest that cutaneous ulcers should be considered as possible side effect of long-term HU therapy and healing of the ulcers can be achieved not only by cessation of the HU treatment, but also by reducing the dose of hydroxyurea for a limited time.

scholarly journals Methemoglobin measure in adult patients with sickle-cell anemia: influence of hydroxyurea therapy

2014 ◽  
Vol 50 (3) ◽  
Author(s):  
Marilia Rocha Laurentino ◽  
Teresa Maria de Jesus Ponte Carvalho ◽  
Talyta Ellen de Jesus dos Santos ◽  
Maritza Cavalcante Barbosa ◽  
Thayna Nogueira dos Santos ◽  
...  
Keyword(s):  
Sickle Cell ◽  
Sickle Cell Anemia ◽  
Adult Patients ◽  
Hydroxyurea Therapy

Multiple pigmented nail bands during hydroxyurea therapy: An uncommon finding

1991 ◽  
Vol 24 (6) ◽  
pp. 1016-1017 ◽  
Author(s):  
Stephanie Vomvouras ◽  
Anita S. Pakula ◽  
John M. Shaw
Keyword(s):  
Hydroxyurea Therapy

scholarly journals Drug repurposing: Hydroxyurea therapy improves the transfusion-free interval in HbE/beta-thalassemia–major patients with Xmn1 polymorphism

2021 ◽  
Author(s):  
Debojoyti Ghosh ◽  
Amrita Panja ◽  
Dipankar Saha ◽  
Uma Banerjee ◽  
Asok Kumar Dutta ◽  
...  
Keyword(s):  
High Performance ◽  
Complete Blood Count ◽  
Drug Repurposing ◽  
Fetal Hemoglobin ◽  
Thalassemia Major ◽  
Beta Thalassemia ◽  
Drug Candidate ◽  
Free Interval ◽  
Pcr Rflp ◽  
Hydroxyurea Therapy

AbstractAimsHbE/β-thalassemia is the prevalent form of severe β-thalassemia in Asian countries. Hydroxyurea (HU) is the most common drug used for the management of sickle-cell anemia but not thalassemia. Here, we aimed to assess clinical HU response among patients with HbE/β-thalassemia with respect to Xmn1 γGglobin polymorphism and elucidate the association between this polymorphism and HU response efficacy.MethodsWe enrolled 49 transfusion-dependent patients with HbE/β-thalassemia. Fetal hemoglobin level was measured using High-performance liquid chromatography (HPLC) and complete blood count was determined pre- and post-HU therapy. Polymerase chain reaction–Restriction fragment length polymorphism (PCR-RFLP) was performed for genotyping Xmn1 γGglobin polymorphism.ResultsA total of 30 (61.22%) patients were found to be responders, whereas the remaining 19 (38.78%) were non-responders. We found 33 patients with heterozygous (C/T) and three with homozygous mutant (T/T) genotype status. We obtained a statistically significant correlation (p < 0.001) between Xmn1 polymorphism and transfusion-free interval. Patients with Xmn1 polymorphism were found to be good responders for HU therapy and showed increased hemoglobin levels.ConclusionsOur findings indicate that HU is a potential drug candidate for thalassemia management, particularly HbE/β-thalassemia. The results hold implications in repurposing HU as an effective and efficient therapy for HbE/β-thalassemia.

Sign in / Sign up

Export Citation Format

Share Document